In situ cancer vaccination: An IL-12 defective vector/replication- competent herpes simplex virus combination induces local and systemic antitumor activity

Journal of Immunology

Volumn 160, Issue 9, 1998, Pages 4457-4464

  Toda, Masahiro ^a   Martuza, Robert L ^a   Kojima, Hidefumi ^c   Rabkin, Samuel D ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM REPEAT; TUMOR GROWTH; VACCINATION; VERO CELL; VIRUS REPLICATION;

ANIMALS; CANCER VACCINES; CERCOPITHECUS AETHIOPS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; VACCINATION; VERO CELLS;

EID: 0032080376     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
2. Mineta, T., S. D. Rabkin, T. Yazaki, W. D. Hunter, and R. L. Martuza. 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1:938.
3. Yazaki, T., H. J. Manz, S. D. Rabkin, and R. L. Martuza. 1995. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55:4752.
4. Toda, M., S. D. Rabkin, and R. L. Martuza. 1997. Intratumoral inoculation of a replication-competent herpes simplex virus, G207, induces an antitumor immune response. Proc. Am. Assoc. Cancer Res. 38:1176.
5. Spaete, R. R., and N. Frenkel. 1982. The herpes simplex virus amplicon: A new eukaryotic defective-virus cloning-amplifying vector. Cell 30:295.
6. Kwong, A. D., and N. Frenkel. 1995. Biology of herpes simplex virus (HSV) defective viruses and development of the amplicon system. In Viral Vectors. Gene Therapy and Neuroscience Applications. M. G. Kaplitt and A. D. Loewy, eds. Academic Press, San Diego, pp. 25-42.
7. Kaplitt, M. G., J. G. Pfaus, S. P. Kleopoulos, B. A. Hanlon, S. D. Rabkin, and D. W. Pfaff. 1991. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol. Cell. Neurosci. 2:320.
8. Desai, B. B., P. M. Quinn, A. G. Wolitzky, P. K. A. Mongini, R. Chizzonite, and M. K. Gately. 1992. IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol. 148:3125.
9. Presky, D. H., H. Yang, L. J. Minetti, A. O. Chua, N. Nabavi, C-Y. Wu, M. K. Gately, and U. Gubler. 1996. A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93:14002.
10. Scott, P. 1993. IL12: initiation cytokine for cell-mediated immunity. Science 260:496.
11. Trinchieri, G. 1994. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
12. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Huhbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
13. Mu, J., J. P. Zou, N. Yamamoto, T. Tsutsui, X. G. Tai, M. Kobayashi, S. Herrmann, H. Fujiwara, and T. Hamaoka. 1995. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 55:4404.
14. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693.
15. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol 153:1697.
16. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.
17. Tahara, H., H. J. Zeh III, W. J. Storkus, I. Pappo, S. Watkins, U. Gubler, S. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182.
18. Colombo, M. P., M. Vagliani, F. Spreafico, M. Parenza, C. Chiodoni, C. Melani, and A. Stoppacciaro. 1996. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56:2531.
19. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. Zeh III, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466.
20. Bramson, J. L., M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham. 1996. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7:1995.
21. Meko, J. B., J. H. Yim, K. Tsung, and J. A. Norton. 1995. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 55:4765.
22. Rao, J. B., R. S. Chamberlain, V. Bronte, M. W. Carroll, K. R. Irvine, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1996. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156:3357.
23. Yu, W. G., N. Yamamoto, H. Takenaka, J. Mu, X. G. Tai, J. P. Zou, M. Ogawa, T. Tsutsui, R. Wijesuriya, R. Yoshida, S. Herrmann, H. Fujiwara, and T. Hamaoka. 1996. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol. 8:855.
24. Zitvogel, L., P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J. Maeurer, R. L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, and M. T. Lotze 1996. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26: 1335.
25. Fearon, E. R., T. Itaya, B. Hunt, B. Vogelstein, and P. Frost. 1988. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 35:2975.
26. Huang, A. Y. C., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, D. M. Pardoll, and E. M. Jaffee. 1996. The immunodominant major histocompalibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93:9730.
27. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25:137.
28. Corbett, T. H., D. P. J. Griswold, B. J. Roberts, J. C. Peckham, and F. M. J. Schnabel. 1975. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35:2434.
29. Brattain, M. G., J. Strobel-Stevens, D. Fine, M. Webb, and A. M. Sarrif. 1980. Establishment of mouse colonie carcinoma cell lines with different metastatic properties. Cancer Res. 40:2142.
30. Harding, H. E., and R. D. Passey. 1930. A transplantable melanoma of the mouse. J. Pathol. Bacteriol. 33:417.
31. Bleehen, S. S. 1974. Ultrastructural studies on tumors and cell cultures of the Harding-Passey mouse melanoma. Br. J. Dermatol. 90:637.
32. Cailleau, R., M. Olive, and Q. V. Crucigar. 1978. Long term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911.
33. Kim, K. J., C. Kanellopoulos-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:549.
34. Schoenhaut, D. S., A. O. Chua, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, W. McComas, P. C. Familletti, M. K. Gately, and U. Gubler. 1992. Cloning and expression of murine IL-12. J. Immunol. 148:3433.
35. Wilkinson, V. L., R. R. Warrier, T. P. Truitt, P. Nunes, M. K. Gately, and D. H. Presky. 1996. Characterization of anti-mouse IL12 monoclonal antibodies and measurement of mouse IL12 by ELISA. J. Immunol. Methods 189:15.
36. Van den Eynde, B., B. Lethe, B. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
37. Kojima, H., N. Shinohara, S. Hanaoka, Y. Someya-Shirota, Y. Takagaki, H. Ohno, T. Saito, T. Katayama, H. Yagita, K. Okumura, Y. Shinkai, F. W. Alt, A. Matsuzawa, S. Yonehara, and H. Takayama. 1994. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1:357.
38. Randazzo, B. P., S. Kesari, R. M. Gesser, D. Alsop, J. C. Ford, S. M. Brown, A. MacLean, and N. W. Fraser. 1995. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211:94.
39. Noguchi, Y., E. C. Richards, Y.-T. Chen, and L. J. Old. 1995. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
40. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbared, and M. Murphy. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol. 6:157.
41. Sarmiento, U. M., J. H. Riley, P. A. Knaack, J. M. Lipman, J. M. Becker, M. K. Gately, R. Chizzonite, and T. D. Anderson. 1994. Biological effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest. 71:862.
42. Wang, M., V. Bronte, P. W. Chen, L. Gritz, D. Panicali, S. A. Rosenberg, and N. P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685.
43. Bramson, J., M. Hitt, W. S. Gallichan, K. L. Rosenthal, J. Gauldie, and F. L. Graham. 1996. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7:333.
44. Vagliani, M., M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, and M. P. Colombo. 1996. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res. 56:467.
45. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
46. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class 1 molecules. Science 267:243.
47. Reis e Sousa, C., and R. N. Germain. 1995. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182:841.
48. D'Andrea, A., M. Rengaraju, N. M. Valiante, J. Chehimi, M. Kubin, M. Aste, S. H. Chan, M. Kobayashi, D. Young, E. Nickbarg, R. Chizzonite, S. F. Wolf, and G. Trinchieri. 1992. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 176:1387.
49. Kanangat, S., J. Thomas, S. Gangappa, J. S. Babu, and B. T. Rouse. 1996. Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression: implications in immunopathogenesis acid protection. J. Immunol. 156:1110.